Goldman Sachs says a period of underperformance for LivaNova stock could be ending and see shares gain more than 20%.
Roman initiated coverage of the medical device stock with a buy rating and a $65 per share price target.
Shares have advanced roughly 3% in 2024, significantly underperforming the S & P 500's nearly 20% gain.
Roman ties the underperformance to "strategic shifts in the business and pipeline setbacks" for much of the year which also pressured LivaNova's earnings.
LIVN YTD mountain LivaNova stock.
Persons:
Goldman Sachs, David Roman, LivaNova